EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming

Remi Adelaiye‐Ogala(Roswell Park Comprehensive Cancer Center), Роберто Пили(Jacobs Institute), Yong Zang(Indiana University School of Medicine), Scott A. Persohn(Indiana University Health), Nur P. Damayanti(University of Indianapolis), Janaiah Kota(Ultragenyx Pharmaceutical (United States)), Sreenivasulu Chintala(UC San Diego Health System), W. Andy Tao(Purdue University West Lafayette), Brian P. McCarthy(Indiana University Health), Giulio Draetta(The University of Texas MD Anderson Cancer Center), Michael Buck(University at Buffalo, State University of New York), Sreevani Arisa(Indiana University – Purdue University Indianapolis), Justin A. Budka(Gilead Sciences (United Kingdom)), Milan Radovich(Caris Life Sciences (United States)), Joseph Irudayaraj(Carle Foundation Hospital), May Elbanna(Indiana University Health), Paul R. Territo(Indiana University Health), Chuan-Chih Hsu(Purdue University West Lafayette), Kiersten Marie Miles(Roswell Park Comprehensive Cancer Center), Piergiorgio Pettazzoni(Roche (Switzerland)), Heike Keilhack(Epizyme (United States)), Mary W. Ferris(Indiana University Bloomington), Justine Arrington(Purdue University West Lafayette), Eric Ciamporcero(Roswell Park Comprehensive Cancer Center), Mukund Seshadri(Roswell Park Comprehensive Cancer Center), Li Shen(The University of Texas MD Anderson Cancer Center), Bradley A. Hancock(Indiana University – Purdue University Indianapolis), Ashley Orillion(Roswell Park Comprehensive Cancer Center), Peter C. Hollenhorst(Indiana University Bloomington)
Cancer Research
October 4, 2017
Cited by 74


Related Papers